Clinical Trial Update: Use Of Fragmin In Hemodialysis [Phase 3]

View source ↗

Summary

Pfizer's Phase 3 trial evaluating Fragmin (dalteparin) for use in hemodialysis in patients with chronic kidney disease has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• FRAGMIN (DALTEPARIN SODIUM)

Snippet

Sponsor: Pfizer | Conditions: Chronic Renal Failure | Phase 3 | Status: COMPLETED | Results posted: 2016-12-29